Glioblastoma Multiforme Treatment Market Assessment, By Drug [Temozolomide, Lomustine, Bevacizumab, Others], By Treatment [Surgery, Radiation, Chemotherapy, Targeted Therapy, Others], By End-user [Hospitals and Clinics, Ambulatory Surgical Centers, Others

Glioblastoma Multiforme Treatment Market Assessment, By Drug [Temozolomide, Lomustine, Bevacizumab, Others], By Treatment [Surgery, Radiation, Chemotherapy, Targeted Therapy, Others], By End-user [Hospitals and Clinics, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, 2017-2031F

Global glioblastoma multiforme treatment market is projected to witness a CAGR of 8.78% during the forecast period 2024-2031, growing from USD 2.91 billion in 2023 to USD 5.71 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Growth in global glioblastoma multiforme treatment market is being driven by several factors such as increase in the prevalence of glioblastoma multiforme among the population, the development of innovative therapeutical drugs, and tremendous growth in the pharmaceutical and drug discovery industry. Government initiatives, growing investments by key market players to develop quality and efficient drugs, along with a supportive regulatory framework and collaborative ventures between medical device manufacturers and pharmaceutical companies will further promote the growth of the global glioblastoma multiforme treatment market.

The global glioblastoma multiforme treatment market is significantly undergoing robust growth due to the increasing prevalence of glioblastoma multiforme worldwide. As glioblastoma multiforme is a fast-growing tumor, it is highly essential to get treatment as early as possible to develop any fatal condition. Glioblastoma multiforme treatment methods such as surgery, chemotherapy, and radiation therapy play a crucial role in increasing the life expectancy of the patients. With the growing cases of glioblastoma, there is an increased demand for glioblastoma multiforme treatments due to which many leading players are continuously involved in launching innovative and efficient therapeutical drugs in their cancer treatment product portfolio, which is further propelling the growth of the global glioblastoma multiforme treatment market.

Government initiatives such as granting funds are being initiated to improve research and development in the market to improve medical facilities and provide efficient treatment to the patients. Product launches by key market players, along with increased collaboration activities such as mergers and acquisitions, partnership agreements, and new distribution agreements, drive the global glioblastoma multiforme treatment market. Moreover, several market leaders are undergoing extensive research and development in the market to launch innovative and efficient drugs. Celldex Therapeutics that develops targeted immunotherapy and biologics for the treatment of different types of cancers, announced that its latest drug “Varlilumab” is under clinical trial phase II and is most likely to progress into phase III.

Increasing Prevalence of Glioblastoma Multiforme

The demand for glioblastoma multiforme treatment is increasing significantly due to the rising number of glioblastoma multiforme cases worldwide. Glioblastoma is a leading cause of death among the cancer patients globally, as it is a type of cancer that spreads faster, leading to further health complications. According to an article published in “UT Southwestern Medical Center”, globally, more than 300,000 cases of glioblastoma are diagnosed every year. It states that it is the most common primary malignant brain cancer in the adult population. The survival time for glioblastoma patients is only 15 to 18 months on an average, which further emphasizes the need for research and development to bring efficient treatment process that can increase the survival rate of the patients.

Integration of AI For Expediting Drug Development Process

The use of artificial intelligence in pharmaceutical companies is becoming more significant, due to its huge potential to analyze and generate synthesis pathways during the drug development process, as well as optimize clinical trial designs. Leading players in the glioblastoma multiforme treatment market are continuously involved in using the latest advanced technologies such as artificial intelligence and machine learning to enhance the research and development process, to bring more efficient therapeutic drugs, that can be beneficial in the treatment process of cancer.

For instance, in October 2023, Lantern Pharma Inc., using its AI-based platform, “RADR”, announced that its latest innovative drug “LP-184” for the treatment of glioblastoma was published in the American Association for Cancer Research Journal. It states that LP-184 is a unique small molecule that has highly efficient CNS penetration and low nanomolar activity. With the help of its AI platform RADR, LP-184 is developed in such a way that it can repair damaged DNA. Moreover, it has been proven to be effective for patients with temozolomide resistance.

Radiation Therapy Dominates the Market in Terms of Treatment Methods

Among the different treatment methods for glioblastoma multiforme patients, the application of radiation therapy is increasing significantly. Radiation therapy plays a crucial part in the treatment of glioblastoma multiforme. After the surgical removal of a tumor, radiation therapy alone or in combination with chemotherapy is recommended to kill the remaining cancer cells and limit the growth of cancer cells in the future. Several companies are involved in developing innovative therapeutics to make radiation therapies more efficient. For instance, in December 2023 Shuttle Pharmaceuticals Holdings, Inc. announced application submission of an investigational new drug (IND) to the FDA, to support the company in the development of Ropidoxuridine in the next phase of the clinical trial. Ropidoxuridine is a radiation sensitizer, that is used in radiation therapy to treat glioblastoma multiforme. The innovative approach aims to increase cancer survival rates and prolong a patient’s life.

Hospitals Hold a Major Share in Glioblastoma Multiforme Treatment Market

Among the end-user segment, hospitals account for the highest market share in the global glioblastoma multiforme treatment market. The increasing global population and rising number of hospitals are expected to cater to the demands and the dominance of the segment in the market. Glioblastoma multiform is an aggressive brain tumor that requires different treatments such as surgery, chemotherapy, and radiation therapy. Hospitals provide all these facilities, along with highly qualified surgeons and healthcare providers, which helps smoothen a patient’s journey throughout the entire pathway from diagnosis to follow up and assessment. As the prevalence of cancer such as glioblastoma multiforme is increasing, the demand for hospitals in developed as well as developing countries are increasing, due to which countries are increasing the number of hospitals with advanced diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and more hospitals are under construction. Increased availability of a variety of treatment facilities in the healthcare setting, along with increased trust among the population regarding the reliability and quality of healthcare facilities provided in the hospitals is further driving the growth of hospital segment in the overall market.

North America Holds Significant Market Share

North America dominates global glioblastoma multiforme treatment market, due to its well-developed and highly efficient healthcare infrastructure and availability of the latest and advanced surgical techniques and therapeutical drugs for the treatment of glioblastoma multiforme. The growing prevalence of glioblastoma multiforme among the United States population is the prime factor, that is driving the growth of this market.

For instance, according to the “National Brain Tumor Society”, in the United States, more than 10,000 individuals are affected by glioblastoma multiforme every year and it is estimated that out of all primary malignant brain tumors, 50.1% account for glioblastoma multiforme. The increasing prevalence requires efficient treatment such as surgeries, chemotherapy, and radiation therapy to increase the life span of the patients affected by this disease. Due to this, the demand for glioblastoma multiforme treatment is increasing in North America. Additionally, increased research and development in the market, along with the presence of key market players such as Amgen Inc and Merck & Co. further accelerate the demand for the global glioblastoma multiforme treatment market in the region.

Future Market Scenario (2024 – 2031F)

The global glioblastoma multiforme treatment market is expected to grow in the future, primarily due to increasing prevalence of glioblastoma multiforme worldwide. As the prevalence is increasing, pharmaceutical companies are constantly involved in extensive research and development of innovative therapeutical drugs for the treatment of the disease, along with mergers and acquisitions activities to enhance their product portfolio and expand their global market.

Additionally, the growth of the pharmaceutical industry, increased investments by organizations and government, frequent product launches, and increased FDA approvals by the regulatory bodies further lead to the growth of the global glioblastoma multiforme treatment market. For instance, in January 2024, Roche announced that its latest drug “Atezolizumab” is under clinical trial phase II and is most likely to get the FDA approval soon. The drug is expected to provide efficient treatment to the patients suffering from glioblastoma multiforme. These frequent product launches and favorable regulatory frameworks are further expected to escalate the growth of the market in the forecast period.

Key Players Landscape and Outlook

In the glioblastoma multiforme treatment market, pharmaceutical firms and biotechnological companies are consistently forming strategic partnerships and distribution agreements to enhance their productivity and global business. These collaboration activities play a crucial role in propelling the global glioblastoma multiforme treatment market's expansion. The strategic partnerships agreements, enable firms to gain in-depth insights into the market, strategically use each other's resources, markets, and technologies, and invest in research and development activities to bring innovative drug discovers and technological advancements in the treatment methods. Distribution agreements allow companies to expand their market presence globally. These collaborative initiatives promote innovation and expertise in product development, which improves patient health outcomes and contributes to the enduring and robust growth of the global glioblastoma multiforme treatment market.

For instance, in September 2023, Double Bond Pharmaceutical International AB, which is a pharmaceutical company that develops therapeutical drugs against cancer, announced its collaboration with Vivo Biopharma LLC, which is a subsidiary of Sauvie Inc. The collaboration will allow asset purchase and transition agreements for DBP’s SI-053, which is a locally acting formulation of temozolomide, developed for the treatment of glioblastoma. As this latest drug has the potential to increase survival rate in patients suffering from glioblastoma, it is expected that the agreement will provide quality and advanced treatment to cancer patients and will support in elevating the market globally.